Author

James D. Brien

University of KentuckyORCID 0000-0002-1670-8041Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:mouse· 4 Research Focus:drug response / drug discovery· 2 Assay:multiome· 1

Frequent Co-Authors

Amelia K. PintoiD· 4 shared E. Taylor StoneiD· 3 shared Adrianus C. M. BooniD· 1 shared Alec J. HirschiD· 1 shared Alexandria M. DicksoniD· 1 shared Angélica Peña RosadoiD· 1 shared Ashley Zalla· 1 shared Carolina B. LópeziD· 1 shared

Activity by Year

2024-2025 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

Amelia K. PintoORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

mRNA-LNP Vaccines Encoding for Dengue Optimized prM/ENV Proteins Induce Protective Immunity without ADE

Enzo LaMontia-Hankin, Clayton J. Wollner, E. Taylor Stone, Angélica Peña Rosado, Jill Pflugheber, Ashley Zalla, Sebastian Nieto, Amelia K. Pinto, James D. Brien, Justin M. Richner

The paper develops mRNA-LNP vaccines encoding optimized prM/ENV proteins for all four DENV serotypes that induce protective immunity and reduce antibody-dependent enhancement.

bioRxiv · Jul 21, 2025 · PreprintMicrobiology

The TLR7/8 agonist INI-4001 enhances the immunogenicity of a Powassan virus-like-particle vaccine

Michael W. Crawford, Walid Abdelwahab, Karthik Siram, Christopher J. Parkins, Henry F. Harrison, E. Taylor Stone, Samantha R. Osman, Dillon Schweitzer, David J. Burkhart, Amelia K. Pinto, James D. Brien, Jessica Louise Smith, Alec J. Hirsch

This paper develops a Powassan virus-like-particle (POW-VLP) vaccine adjuvanted with INI-4001, showing it enhances immunogenicity, reduces viral burden, and provides full protection in mice.

npj Vaccines · Jul 16, 2025Peer-reviewedImmunology

Metabolic syndrome enhances SARS-CoV-2 disease severity and reduces mRNA vaccine efficacy in a mouse model

Elizabeth Geerling, E. Taylor Stone, Danielle H. Carpenter, Alexandria M. Dickson, James D. Brien, Amelia K. Pinto

This study shows that metabolic syndrome worsens SARS-CoV-2 disease and lowers vaccine effectiveness in mice.

bioRxiv · Jan 15, 2025 · PreprintImmunology

DDO-adjuvanted influenza A virus nucleoprotein mRNA vaccine induces robust humoral and cellular type 1 immune responses and protects mice from challenge

Victoria Gnazzo, Hanaa Saleh, Ítalo A. Castro, Adrianus C. M. Boon, Amelia K. Pinto, James D. Brien, Carolina B. López

This paper tests DDO268 as an adjuvant for an influenza A virus nucleoprotein mRNA vaccine in mice, showing enhanced immune responses and protection against viral challenge.

mBio · Dec 18, 2024Peer-reviewedImmunology